A Real-World Study on the Efficacy, Safety, and Quality of Life of Different Treatment Approaches… (NCT07409415) | Clinical Trial Compass
CompletedNot Applicable
A Real-World Study on the Efficacy, Safety, and Quality of Life of Different Treatment Approaches for Post-Chemotherapy Neutropenia in Cancer Patients
China3,000 participantsStarted 2024-02-15
Plain-language summary
This is a multi-center, retrospective + prospective, real-world observational study. It aims to investigate, through a relatively large sample size, the effectiveness and safety of different treatment approaches for preventing and managing neutropenia in cancer patients after chemotherapy. Additionally, it seeks to observe the impact of different treatment management models on the quality of life of cancer patients undergoing chemotherapy, so as to provide real-world evidence for selecting different treatment strategies for cancer patients after chemotherapy in the future.
Who can participate
Age range14 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients diagnosed with non-myeloid malignant tumors (such as breast cancer, lung cancer, colorectal cancer, gynecological cancers, esophageal cancer, head and neck cancers) through imaging, histopathological examination, etc.
✓. Patients who have received at least two cycles of chemotherapy.
✓. Patients with a white blood cell (WBC) count \> 3.0 × 10⁹/L or an absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L before chemotherapy.
✓. Patients with osteosarcoma or lymphoid leukemia must be ≥ 14 years of age; patients with other cancer types must be ≥ 18 years of age.
✓. Patients who voluntarily agree to participate in this study.
✓. Patients who do not develop serious complications after chemotherapy.
Exclusion criteria
✕. Patients with psychiatric disorders.
✕. Patients with language or communication barriers.
✕. Patients with severe dysfunction of the liver, kidneys, heart, or lungs.
What they're measuring
1
Effectiveness: Incidence of FN and Grade 3/4 Neutropenia
Timeframe: Observe for 14 days after each chemotherapy, at least two chemotherapy cycles and at most eight chemotherapy cycles (14 or 21 days per cycle).
Trial details
NCT IDNCT07409415
SponsorHuazhong University of Science and Technology